January 21, 2021
Sapreme Appoints Henrik Luessen as Chief Business Officer
December 17, 2020
Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors
October 27, 2020
Sapreme Appoints Miriam Bujny as Chief Development Officer
September 28, 2020
Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society
Sapreme will be taking part in a number of conferences in September 2021. Details will be available soon.
June 17th, 2021
Sapreme presented data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.
Sapreme’s SPT001 compound significantly improves intracellular release of targeted antisense oligonucleotides (ASO’s) and thereby also their therapeutic efficacy. In addition to oligonucleotides, SPT001 has also been demonstrated to enhance delivery of other targeted payloads such as antibody-conjugated toxins.
The presentation and Q&A session was hosted on June 17th 2021 via the summit’s virtual stage and platform.
September 28th, 2020
Guy Hermans (CEO) and Ruben Postel (CSO) presented “Efficient, targeted cytoplasmic delivery of oligonucleotides via Sapreme’s endosomal escape enhancers” and “SPT001 enhanced mAb-oligo conjugates: efficient delivery beyond the liver”, respectively, at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society.
Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.
Guy Hermans, CEO
+31 30 760 09 76
For Media Inquiries, please contact:
Eva Mulder or Valeria Fisher
+49 89 238 877 30